Transfusion effect of random donor platelet and single donor platelet in thrombocytopenic patients at tertiary care hospital of South Gujarat
DOI:
https://doi.org/10.18203/2320-6012.ijrms20172983Keywords:
Corrected count increment, Percentage recovery, Platelet apheresis, Random donor platelet, Single donor plateletAbstract
Background: Platelet transfusion plays a key role in therapy for the patients with thrombocytopenia. Superiority of Single donor platelet (SDP) over Random donor platelet (RDP) transfusions is largely assumed, but unproven. Platelet Rich Plasma-Platelet concentrate (PRP-PC) and Apheresis-PC were prepared and their therapeutic efficacy were assessed in thrombocytopenic patients.
Methods: This study included 60 transfusion episodes consisting of 30 SDP and 30 RDP (147units of RDP). The post transfusion efficacy of transfused platelets was assessed at 1 hour and 24 hours by corrected count increment (CCI) and percentage recovery (PR). Paired ‘t’-test was used for statistical analysis and a probability of p<0.05 was used to reject null hypothesis.
Results: The mean platelet dose of SDP (n=30) and RDP (n=30) was 2.86±1.05 x 1011 and 2.36±0.54 x 1011 respectively. The mean platelet increments of SDP at 1 hour and 24 hours were 38±18.1 x 103/μl and 37.3±20.7x 103/μl. The mean platelet increments of RDP at 1 hour and 24 hours were 28.5±11.4 x 103/μl and 26 ±11.6 x 103/μl. The mean CCI of SDP at 1hour and 24 hours were 21.4 ±7.3 x 103/μl and 20.8±7.4 x 103/μl respectively. The mean CCI of RDP at 1hour and 24 hours were 18.5±6.3x 103/μl and 17.4±7.6 x 103/μl respectively.
Conclusions: Post-transfusion increments were significantly higher in patients who received SDP as compared to RDP, but the CCI and PR were comparable in both groups of patients.
References
Michelsen AD. Flowcytometry, A clinical test of platelet function. Blood. 1996;87:4925-36.
Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am. 1990;4:291-311.
Wallace EL, Churchill WH, Surgenor DM. Collection and transfusion of blood and blood components in the United States, 1992. Transfus. 1995;35:802-12.
Rinder HM, Smith BR. In vitro evaluation of stored platelets: Is there hope for predicting post-transfusion platelet survival and function. Transfus. 2003;43:2-6.
Hogman CF, Eriksson L, Wallvik J, Payrat JM. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5 CPD Erythro-sol Opti-system. Vox Sang. 1997;73:212-9.
O’Connell B, Lee EJ, Schiffer CA. The value of 10 minutes post transfusion platelet counts. Transfus. 1998;28:66-7.
Anderson NA, Gray S, Copplestone JA, Chan DC, Hamon M, Prentice AG, et al. A prospective randomized study of three types of platelet concentrates in patients with hematological malignancy, corrected platelet count increments and frequency of non-haemolytic febrile transfusion reactions. Transfus Med. 1997;7:9-33.
Singh RP, Marwaha N, Malhotra P, Dash S. Therapeutic efficacy of different types of platelet concentrates in thrombocytopenic patients. Indian J Hematol Blood Transfus. 2008;24(1):16-22.
Norol F, Bierling P, Roudot-Thoraval F, Lecoeur F, Rieux C, Lavaux A, et al. Platelet transfusion, A dose-responsestudy. Blood. 1998;92:1448-53.
Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2007;40(5):461-4.
Ness P, Campbell L, Sally A. Single donor versus pooled random donor platelet concentrates. Current Opinion Haematol. 2001;8(6):392-6.
